What MOUNJARO® Is Used For

MOUNJARO® is prescribed for adults with type 2 diabetes mellitus who need additional support in managing blood sugar. It is also used for weight management when combined with diet and physical activity. Treatment is recommended for individuals with a Body Mass Index (BMI) ≥30 kg/m², or those with a BMI ≥27 kg/m² who also have weight-related conditions such as hypertension, cardiovascular disease, or sleep apnoea.

• Helps improve glycaemic control in type 2 diabetes.

• Supports weight loss and maintenance in adults with obesity or overweight.

• Works best alongside healthy eating and regular exercise.

• Suitable as monotherapy or in combination with other diabetes medications.

What Makes MOUNJARO® a Good Choice

MOUNJARO® offers a flexible, once-weekly treatment that supports both blood sugar control and weight loss. Its stepwise dosing reduces the risk of side effects while ensuring effectiveness.

• Once-weekly injection for convenience.

• Can be combined with oral antidiabetic medicines or insulin.

• Available in a range of doses, allowing gradual escalation.

• Shown in trials to reduce HbA1c and body weight.

Different MOUNJARO® Products

MOUNJARO® comes in multiple strengths, making it easier to tailor treatment. Each KwikPen® contains four doses.

• 2.5 mg/dose KwikPen® (starter dose, 4 doses per pen).

• 5 mg/dose KwikPen® (maintenance option, 4 doses per pen).

• 7.5 mg/dose KwikPen® (step-up option, 4 doses per pen).

• 10 mg/dose KwikPen® (commonly used maintenance, 4 doses per pen).

• 12.5 mg/dose KwikPen® (intermediate step, 4 doses per pen).

• 15 mg/dose KwikPen® (maximum dose, 4 doses per pen).

Best Uses and Target Areas

MOUNJARO® is not a first-line treatment but is valuable when other methods are not enough. It is effective for both metabolic control and long-term weight reduction.

• Diabetes control: Helps patients reach blood glucose targets.

• Obesity management: Supports sustained weight loss.

• Overweight patients with comorbidities: Recommended when extra risk factors exist.

• Flexible treatment: Can be used alone or with other diabetes medicines.

Key Ingredients in MOUNJARO®

The main component is tirzepatide, a dual GIP and GLP-1 receptor agonist. It is combined with excipients that stabilize the solution.

• Tirzepatide: Active substance, available in multiple strengths.

• Excipients: Includes benzyl alcohol (5.4 mg per 0.6 mL dose), glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, and water for injections.

• Sodium content: Less than 1 mmol per dose (sodium-free).

• Appearance: Clear, colourless to slightly yellow solution.

How It’s Given (Injection Guide for MOUNJARO®)

MOUNJARO® is delivered by subcutaneous injection once per week. Patients can self-administer after proper training.

• Injection sites: Abdomen, thigh, or upper arm.

• Dosing schedule:

  • Start with 2.5 mg weekly for 4 weeks.

  • Increase in 2.5 mg steps every ≥4 weeks until desired dose.

  • Maximum dose: 15 mg weekly.

• Missed dose:

  • If within 4 days, take it as soon as possible.

  • If more than 4 days, skip and continue with next dose.

• Rotate injection sites to prevent irritation.

Storage and Expiry Details

Proper storage is essential to maintain product quality.

• Unopened pens: Refrigerate at 2–8 °C.

• Do not freeze; discard if frozen.

• After first use: May be stored at ≤30 °C for 30 days.

• Discard after 30 days, even if solution remains.

• Keep out of reach of children.

Possible Side Effects to Know

Like all medicines, MOUNJARO® may cause side effects, most often affecting the digestive system. These usually occur early in treatment and lessen over time.

• Very common: Nausea, diarrhoea, vomiting, constipation, abdominal pain.

• Common: Decreased appetite, dyspepsia, dizziness, fatigue, mild injection-site reactions.

• Occasional: Gallbladder issues (e.g., cholelithiasis, cholecystitis).

• Rare: Acute pancreatitis, severe allergic reactions (anaphylaxis, angioedema).

• Laboratory changes: Elevated amylase and lipase levels.

Quick Answers About MOUNJARO®

• How often is it taken? Once weekly.

• Does it replace insulin? No, but it can be used alongside insulin with dose adjustment.

• Who should avoid it? Those with hypersensitivity to tirzepatide or severe gastrointestinal disease.

• What if I’m pregnant or breastfeeding? It is not recommended during pregnancy or lactation.

• Is it safe long-term? Clinical studies show ongoing effectiveness, but monitoring is required.

Where to Buy MOUNJARO®

Healthcare professionals and clinics can buy MOUNJARO® online or through verified distributors. Contact the sales representatives on Maylips